US-UK trade deal costs NHS 45bn

US-UK drug deal could result in 229,000 excess deaths in England, analysis suggests Analysis reveals extent of impact on NHS of placating Donald Trump over price of British medicine exports. The NHS will have to divert £45bn from essential services to pay for new medicines under the terms of the UK-US trade deal agreed last December, leading to more than 200,000 avoidable deaths of patients, analysis has found. Ministers have defended the deal as a way of helping British drug exports to the US avoid tariffs, and giving patients in England access to potentially life-extending drugs that would otherwise be denied..

The trade deal was hailed as a major breakthrough at the time of its announcement, with ministers highlighting the benefits of securing a deal worth billions of pounds to the UK’s pharmaceutical sector. However, new analysis suggests that the impact on the NHS could be catastrophic, with researchers claiming that the money will have to come from diverting funds from essential services, including cancer treatment, mental health services, and primary care. This could lead to a shortage of life-saving treatments and increased waiting times for patients, exacerbating existing health inequalities..

The analysis, carried out by researchers at the University of York, used a range of data to estimate the impact of the deal on the NHS. They found that the cost of the deal would be £45bn over five years, which would have to be paid for by diverting funds from essential services. This would have a significant impact on the NHS’s ability to deliver services, particularly in the short term..

According to the researchers, the NHS’s ability to respond to future health crises, such as a major pandemic, would also be compromised by the deal. They warn that the impact could be felt for decades to come, as the NHS struggles to recover from the blow. The UK government has maintained that the deal will be worth it in the long run, as it gives British drugs exports access to the massive US market..

However, critics argue that the short-term cost to the NHS is too high to justify the benefits. They also point out that the deal may not even achieve its goals, as some US states have already indicated that they may impose their own tariffs on British medicines. The NHS is already facing significant challenges, including a shortage of staff and a backlog of patients waiting for treatment..

The impact of the deal could be felt most keenly in these areas, as the NHS struggles to cope with the additional pressures. Patients’ groups have expressed alarm at the findings, warning that the deal could have devastating consequences for those in need of medical treatment. The UK’s spending review is due to take place later this year, and critics are calling on the government to reassess the deal and its impact on the NHS..

They argue that the government should prioritize the NHS’s needs and find alternative ways of securing access to the US market for British medicines. Ministers have been accused of being too quick to agree to the deal without fully considering its implications for the NHS. Critics argue that they should have demanded better terms from the US government, including greater flexibility on pricing and a commitment to improving access to medicines..

The impact of the deal could also have wider implications for the NHS’s ability to innovate and develop new treatments. The £45bn diversion of funds from essential services could limit the NHS’s ability to invest in new technologies and treatments, putting the UK’s reputation for medical innovation at risk. The UK’s opposition parties have been quick to seize on the findings, accusing the government of putting the interests of big pharma ahead of those of patients..

They argue that the deal is a bad deal for the NHS and for patients, and that the government should have negotiated better terms. However, the UK government still maintains that the deal is a good one, arguing that it will give British drugs exports access to the massive US market and help to create jobs and growth in the sector. The NHS has also come out in support of the deal, arguing that it will bring new medicines to patients and help to improve health outcomes..

The issue is sure to be the subject of intense debate in the coming months, as the NHS grapples with the implications of the deal and attempts to find ways of mitigating its impact. Meanwhile, the people of England are left to wonder what the future holds for their healthcare service, and how they will fare under the new terms. As policymakers and the public continue to debate the merits and drawbacks of the deal, those affected by it – the patients and taxpayers – remain at the forefront of the issue..

The impact of the trade deal is being felt across the country, leaving communities vulnerable to the consequences of the agreement..